

Figure S1. Increased expression of muscle-specific RNAs in myotubes differentiated at complete absence of FBS. Primary human myoblasts ($n=6$) were treated with 1 ng/ml TGF- β 1 (T β), TGF- β 1 plus inhibitor (10 μ M SB431542) (TSB), or vehicle control (Ctrl) for 48 h. Subsequently, myoblasts were differentiated towards myotubes for 5 days in the presence (2%) or absence (0%) of FBS. Expression of mature miRNA (A) miR-499a-5p, (B) miR-208b, (C) miR-146b-5p, (D) miR-139-5p, (E) miR-143-3p, (F) miR-145-5p, (G) miR-181a2-5p, (H) miR-31-5p and mRNA (I) *MYH1*, (J) *MYH2*, (K) *MYH4*, (L) *MYH7* was detected by qPCR. All qPCR data were normalized to individual donors and reference RNU6 (miRNAs) or mean of *RPS28* and *TBP* (mRNA). Individual datapoints are displayed, bars represent mean \pm SD. All data were analyzed using one-way ANOVA with Bonferroni correction, * $p<0.05$, ** $p<0.01$, *** $p<0.001$ vs Ctrl at same FBS concentration, \$ $p<0.05$, \$\$ $p<0.01$, \$\$\$ $p<0.001$ vs T β at same FBS concentration, # $p<0.05$, ## $p<0.01$, ### $p<0.001$ 0% vs 2% FBS.




Figure S2. TGF- β regulates miR-143-3p/145-5p and miR-181a2-5p in myoblasts

Primary human myoblasts (n=6) were treated with 1 ng/ml TGF- β 1 (T β), TGF- β 1 plus inhibitor (10 μ M SB431542) (TSB), or vehicle control (Ctrl) for 48 h. Expression of mature miRNA (A) miR-143-3p, (B) miR-145-5p, (C) miR-181a2-5p was detected by qPCR. All qPCR data were normalized to individual donors and reference RNU6. Individual datapoints are displayed, bars represent mean \pm SD. All data were analyzed using one-way ANOVA with Bonferroni correction, *** p<0.001 vs Ctrl, \$\$ p<0.01, \$\$\$ p<0.001 vs T β .




Figure S3. No miR-181a2-5p induction in low-responders with elevated TGF- β signaling by training. Middle aged sedentary individuals (n=40) were grouped into low-responders (LRE, red) and responders (re, black) based on their improvement (fold change > 1.1) in insulin sensitivity (ISIMats) after 8 weeks of training intervention. (A) Expression of mature miRNA miR-181a2-5p was detected in muscle biopsies by qPCR, normalized to individual donors and reference RNU6. Individual datapoints are displayed, bars represent mean \pm SD. Data were analyzed using one-way ANOVA with Fisher's LSD post-hoc test.




Figure S4. Correlation of miR-143/145 and potential skeletal muscle specific target fold changes after training. Muscle biopsies were taken from middle aged sedentary individuals (n=40) before and after 8 weeks of training intervention. RNA isolated from muscle biopsies was used for transcriptome analyses and detection of miRNAs via qPCR. (A-I) qPCR data were normalized to individual donors and reference RNU6. Correlation analyses were performed between fold changes (after intervention vs. before intervention) of miR-143-3p/145-5p and potential targets. Data were analyzed using Pearson correlation, coefficient r and p -values are indicated.




Figure S5. miR-143/145 downregulate components of skeletal muscle differentiation after 96 h. Primary human myoblasts (n=6) were differentiated towards myotubes for 5 days in the absence of FBS and subsequently transfected with miR-143-3p, miR-145-5p, a combination of miR-143-3p and miR-145-5p, control miR-122-5p, or vehicle control (Ctrl) for 96 h. Expression of mature miRNA (A) miR-143-3p, (B) miR-145-5p was detected by qPCR. (C) mRNA levels of (C) miR-122-5p target *ALDOA*, (D) *MYH1*, (E) *INSR* and (F) *IRS1* were detected by qPCR. All qPCR data were normalized to individual donors and reference RNU6 (miRNAs) or *RPS28* and *TBP* (mRNA). Individual datapoints are displayed, bars represent mean \pm SD. All data were analyzed using one-way ANOVA with Fisher's LSD post-hoc test, * p<0.05, *** p<0.001 vs Ctrl.

		miR143	p vs. Ctrl	miR145	p vs. Ctrl	miR143+145	p vs. Ctrl
Differentiation	<i>MYH1</i>	0.82	0.0304	0.91	n.s.	0.79	0.0179
	<i>MYH2</i>	1.07	n.s.	0.96	n.s.	0.92	n.s.
	<i>MYH4</i>	0.98	n.s.	0.93	n.s.	0.95	n.s.
	<i>MYH7</i>	0.94	n.s.	0.95	n.s.	1.07	n.s.
Targets	<i>ARPP21</i>	0.96	n.s.	0.84	0.0088	0.98	n.s.
	<i>FNBP1</i>	1.19	n.s.	1.29	0.0254	1.12	n.s.
	<i>HDAC4</i>	1.18	n.s.	1.14	n.s.	1.16	n.s.
	<i>HDAC9</i>	1.38	n.s.	1.08	n.s.	1.40	n.s.
	<i>INSR</i>	1.50	n.s.	1.88	n.s.	1.11	n.s.
	<i>IRS1</i>	0.97	n.s.	0.95	n.s.	0.90	n.s.
	<i>OSBPL8</i>	1.07	n.s.	1.03	n.s.	1.09	n.s.
	<i>PLEKHB2</i>	1.05	n.s.	0.97	n.s.	1.01	n.s.
	<i>TP63</i>	0.84	0.0481	1.01	n.s.	0.89	n.s.

Table S1. Regulation of potential targets by miR-143/145 in differentiated skeletal muscle cells after 96 h. Primary human myoblasts (n=6) were differentiated towards myotubes for 5 days in the absence of FBS and subsequently transfected with miR-143-3p, miR-145-5p, a combination of miR-143-3p and miR-145-5p, control miR-122-5p, or vehicle control (Ctrl) for 96 h. Expression of mature miRNA miR-143-3p, miR-145-5p and mRNA levels of potential targets were detected by qPCR. All qPCR data were normalized to individual donors and reference RNU6 (miRNAs) or mean of RPS28 and TBP (mRNA). The mean fold change compared to Ctrl is listed. Statistical analyses were performed on rel. expression values using one-way ANOVA with Fisher's LSD post-hoc test, p<0.05.

RNA	Primer	Cat. Nr.	Protein	Antibody	Cat. Nr.
<i>ARPP21</i>	Hs_ARPP21_3_SG	QT01192562	pAKT[S473]	Cell Signaling	9271L
<i>FNBP1</i>	Hs_FNBP1_1_SG	QT00030198	tAKT	BD	610860
<i>HDAC4</i>	Hs_HDAC4_1_SG	QT00005810	INSR	Cell Signaling	3025
<i>HDAC9</i>	Hs_HDAC9_1_SG	QT00039333	IRS1	Millipore	06-248
<i>INSR</i>	Hs_INSR_1_SG	QT00082810	MyHfast	Sigma Clone MY-32	M4276
<i>IRS1</i>	Hs_IRS1_1_SG	QT00074144	OSBPL8	Abcam	AB60110
<i>MYH1</i>	Hs_MYH1_2_SG	QT01671005	GAPDH	Abcam	AB8245
<i>MYH2</i>	Hs_MYH2_1_SG	QT00082495	donkey anti-rabbit	Licor	926-68023
<i>MYH4</i>	Hs_MYH4_2_SG	QT01668779	donkey anti-mouse	Licor	p26-68022
<i>MYH7</i>	Hs_MYH7_1_SG	QT00000602	goat anti-mouse	Licor	925-68070
<i>OSBPL8</i>	Hs_OSBPL8_1_SG	QT00067102	goat anti-rabbit	Licor	926-32211
<i>PLEKHB2</i>	Hs_PLEKHB2_1_SG	QT00082936			
<i>TP63</i>	Hs_TP63_2_SG	QT02424051			
<i>RPS28</i>	Hs_RPS28_2_SG	QT02310203			
<i>TBP</i>	Hs_TBP_1_SG	QT00000721			
miR-31	hsa-miR-31-5p	MS00003290 / 002279			
miR-139	hsa-miR-139-5p	MS00003493			
miR-143	hsa-miR-143-3p	MS00003514 / 002249			
miR-145	hsa-miR-145-5p	MS00003528 / 002278			
miR-146b	hsa-miR-146b-5p	MS00003542			
miR-181a2	hsa-miR-181a-2-3p	MS00008834 / 000480			
miR-208b	hsa-miR-208b	MS00009058			
miR-499a	hsa-miR-499a-5p	MS00004375			
RNU6	RNU6	MS00033740			

Table S2. Primer Assays and Antibodies

Indicated miRNAs were measured with either Qiagen/TaqMan Assays.